Merck & Co., Inc.
For the period ended Feb 3, 2026. Filed Feb 3, 2026.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Feb 3, 2026 · Filed Feb 3, 2026
Use the contents to explore the available documents and sections.
Contents
EX-99.2 · Table 3c
Table 3c
| 2025 · 2024 · % Change | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1Q | 2Q | 3Q | 4Q | Full Year | 1Q | 2Q | 3Q | 4Q | Full Year | 4Q | Full Year | |
| TOTAL PHARMACEUTICAL | $13,638 | $14,050 | $15,611 | $14,843 | $58,142 | $14,006 | $14,408 | $14,943 | $14,042 | $57,400 | 6 | 1 |
| United States | 7,927 | 8,328 | 9,493 | 8,662 | 34,409 | 6,936 | 7,399 | 8,227 | 7,728 | 30,290 | 12 | 14 |
| % Pharmaceutical Sales | 58.1% | 59.3% | 60.8% | 58.4% | 59.2% | 49.5% | 51.4% | 55.1% | 55.0% | 52.8% | ||
| Europe (1) | 2,384 | 2,551 | 2,675 | 2,839 | 10,449 | 2,555 | 2,572 | 2,620 | 2,498 | 10,246 | 14 | 2 |
| % Pharmaceutical Sales | 17.5% | 18.2% | 17.1% | 19.1% | 18.0% | 18.2% | 17.9% | 17.5% | 17.8% | 17.9% | ||
| Japan | 651 | 604 | 693 | 684 | 2,632 | 802 | 664 | 919 | 813 | 3,199 | -16 | -18 |
| % Pharmaceutical Sales | 4.8% | 4.3% | 4.4% | 4.6% | 4.5% | 5.7% | 4.6% | 6.2% | 5.8% | 5.6% | ||
| Latin America | 589 | 654 | 691 | 644 | 2,578 | 601 | 661 | 730 | 680 | 2,672 | -5 | -4 |
| % Pharmaceutical Sales | 4.3% | 4.7% | 4.4% | 4.3% | 4.4% | 4.3% | 4.6% | 4.9% | 4.8% | 4.7% | ||
| Asia Pacific (other than China and Japan) | 535 | 609 | 593 | 586 | 2,323 | 580 | 595 | 669 | 612 | 2,457 | -4 | -5 |
| % Pharmaceutical Sales | 3.9% | 4.3% | 3.8% | 4.0% | 4.0% | 4.1% | 4.1% | 4.5% | 4.4% | 4.3% | ||
| China (2) | 668 | 407 | 377 | 364 | 1,816 | 1,744 | 1,790 | 996 | 864 | 5,394 | -58 | -66 |
| % Pharmaceutical Sales | 4.9% | 2.9% | 2.4% | 2.5% | 3.1% | 12.5% | 12.4% | 6.7% | 6.2% | 9.4% | ||
| Eastern Europe/Middle East/Africa | 435 | 451 | 365 | 348 | 1,598 | 395 | 353 | 400 | 348 | 1,495 | 0 | 7 |
| % Pharmaceutical Sales | 3.2% | 3.2% | 2.3% | 2.3% | 2.7% | 2.8% | 2.4% | 2.7% | 2.5% | 2.6% | ||
| Canada | 125 | 135 | 134 | 153 | 547 | 138 | 143 | 133 | 144 | 558 | 6 | -2 |
| % Pharmaceutical Sales | 0.9% | 1.0% | 0.9% | 1.0% | 0.9% | 1.0% | 1.0% | 0.9% | 1.0% | 1.0% | ||
| Other | 324 | 311 | 590 | 563 | 1,790 | 255 | 231 | 249 | 355 | 1,089 | 59 | 64 |
| % Pharmaceutical Sales | 2.4% | 2.1% | 3.9% | 3.8% | 3.2% | 1.9% | 1.6% | 1.5% | 2.5% | 1.7% | ||
Sum of quarterly amounts may not equal year-to-date amounts due to rounding.
(1) Europe represents all European Union countries, the European Union accession markets and the United Kingdom.
(2) Gardasil/Gardasil 9 sales in China were $193 million, $0, $0 and $0 in the first, second, third and fourth quarter of 2025, respectively, and $1,253 million, $1,312 million, $517 million and $446 million in the first, second, third, and fourth quarter of 2024, respectively.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.